Genomic approaches to coronary artery disease

Indian Journal of Medical Research

Volumn 132, Issue 11, 2010, Pages 567-578

  Padmanabhan, Sandosh ^a   Hastie, Claire ^a   Prabhakaran, Dorairaj ^b   Dominczak, Anna F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CENTRE FOR CHRONIC DISEASE CONTROL   (India)

Author keywords

Candidate gene; Coronary artery disease; Genetic associations; Metabolomics; Proteomics

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIET; DISEASE SURVEILLANCE; ENVIRONMENTAL FACTOR; EXERCISE; FAMILY HISTORY; FAMILY STUDY; GENE MAPPING; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME; GENOME WIDE ASSOCIATION; GENOMICS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; METABOLOMICS; PHARMACOGENOMICS; PHENOTYPE; PROTEOMICS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY;

CORONARY ARTERY DISEASE; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH DESIGN;

EID: 78649463798     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
2. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94: 16-26.
3. Srinath RK, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005; 366: 1744-9.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
5. Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 2006; 7: 163-73.
6. Lloyd-Jones DM, Nam BH, D'Agostino RB, Sr., Levy D, Murabito JM, Wang TJ, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004; 291: 2204-11.
7. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 1990; 120: 963-9.
8. Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006; 114: 1462-7.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
10. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004; 5: 189-218.
11. Allayee H, Ghazalpour A, Lusis AJ. Using mice to dissect genetic factors in atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1501-9.
12. Zdravkovic S, Wienke A, Pedersen NL, De Faire U. Genetic susceptibility of myocardial infarction. Twin Res Hum Genet 2007; 10: 848-52.
13. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 2002; 252: 247-54.
14. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-32.
15. Petersen L, Nielsen GG, Andersen PK, Sorensen TI. Case-control study of genetic and environmental influences on premature death of adult adoptees. Genet Epidemiol 2002; 23: 123-32.
16. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly D, editors. The metabolic basis of inherited disease. New York: McGraw Hill; 1995. p. 1267-82.
17. Burris TP, Eacho PI, Cao G. Genetic disorders associated with ATP binding cassette cholesterol transporters. Mol Genet Metab 2002; 77: 13-20.
18. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22: 352-5.
19. Wright AF, Hastie ND. Complex genetic diseases: controversy over the Croesus code. Genome Biol 2001; 2: 1-8.
20. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001; 17: 502-10.
21. Lander ES. The new genomics: global views of biology. Science 1996; 274: 536-9.
22. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001; 69: 124-37.
23. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177-82.
24. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
25. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305: 869-72.
26. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004; 114: 1343-53.
27. Altmuller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001; 69: 936-50.
28. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-7.
29. Gimbrone MA, Jr. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol 1999; 155: 1-5.
30. Goldschmidt-Clermont PJ, Creager MA, Lorsordo DW, Lam GKW, Wassef M, Dzau VJ. Atherosclerosis 2005: Recent Discoveries and Novel Hypotheses. Circulation 2005; 112: 3348-53.
31. Little J, Khoury MJ. Mendelian randomisation: a new spin or real progress? Lancet 2003; 362: 930-1.
32. Farrall M, Morris AP. Gearing up for genome-wide gene-association studies. Hum Mol Genet 2005; 14: R157-62.
33. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005; 6: 95-108.
34. Luo AK, Jefferson BK, Garcia MJ, Ginsburg GS, Topol EJ. Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. J Med Genet 2007; 44: 161-5.
35. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356-69.
36. Laird NM, Lange C. Family-based designs in the age of large-scale gene-association studies. Nat Rev Genet 2006; 7: 385-94.
37. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-9.
38. Voight BF, Pritchard JK. Confounding from cryptic relatedness in case-control association studies. PLoS Genet 2005; 1: e32.
39. Zheng G, Freidlin B, Gastwirth JL. Robust genomic control for association studies. Am J Hum Genet 2006; 78: 350-6.
40. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3. 1 million SNPs. Nature 2007; 449: 851-61.
41. Price AL, Patterson N, Yu F, Cox DR, Waliszewska A, McDonald GJ, et al. A genomewide admixture map for Latino populations. Am J Hum Genet 2007; 80: 1024-36.
42. Taylor KD, Norris JM, Rotter JI. Genome-wide association: which do you want first: the good news, the bad news, or the good news? Diabetes 2007; 56: 2844-8.
43. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6: 109-18.
44. Clerget-Darpoux F, Elston RC. Are linkage analysis and the collection of family data dead? Prospects for family studies in the age of genome-wide association. Hum Hered 2007; 64: 91-6.
45. Chen WM, Abecasis GR. Family-based association tests for genomewide association scans. Am J Hum Genet 2007; 81: 913-26.
46. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006; 7: 812-20.
47. Wong MY, Day NE, Luan JA, Chan KP, Wareham NJ. The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement? Int J Epidemiol 2003; 32: 51-7.
48. Pajukanta P, Cargill M, Viitanen L, Nuotio I, Kareinen A, Perola M, et al. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland. Am J Hum Genet 2000; 67: 1481-93.
49. Broeckel U, Hengstenberg C, Mayer B, Holmer S, Martin LJ, Comuzzie AG, et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet 2002; 30: 210-4.
50. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-9.
51. Hauser ER, Crossman DC, Granger CB, Haines JL, Jones CJ, Mooser V, et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet 2004; 75: 436-47.
52. Farrall M, Green FR, Peden JF, Olsson PG, Clarke R, Hellenius ML, et al. Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS Genet 2006; 2: e72.
53. Samani NJ, Burton P, Mangino M, Ball SG, Balmforth AJ, Barrett J, et al. A genomewide linkage study of 1,933 families affected by premature coronary artery disease: The British Heart Foundation (BHF) Family Heart Study. Am J Hum Genet 2005; 77: 1011-20.
54. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76: 505-9.
55. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003; 302: 1578-81.
56. Campbell LA, Kuo CC. Chlamydia pneumoniae--an infectious risk factor for atherosclerosis? Nat Rev Microbiol 2004; 2: 23-32.
57. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: e61-4.
58. Arroyo-Espliguero R, Avanzas P, Jeffery S, Kaski JC. CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart 2004; 90: 983-8.
59. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-92.
60. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003; 170: 187-90.
61. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38: 68-74.
62. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-4.
63. Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, Parish S, et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet 2006; 2: e107.
64. Newton-Cheh C, Hirschhorn JN. Genetic association studies of complex traits: design and analysis issues. Mutat Res 2005; 573: 54-69.
65. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-94.
66. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007; 316: 1491-3.
67. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-6.
68. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316: 1341-5.
69. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in U. K. samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-41.
70. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316: 1488-91.
71. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-53.
72. Schunkert H, Gotz A, Braund P, McGinnis R, Tregouet DA, Mangino M, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21. 3 and coronary artery disease. Circulation 2008; 117: 1675-84.
73. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881-5.
74. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40: 189-97.
75. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40: 161-9.
76. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
77. Morita H, Larson MG, Barr SC, Vasan RS, O'Donnell CJ, Hirschhorn JN, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113: 2697-705.
78. Chan EY. Advances in sequencing technology. Mutat Res 2005; 573: 13-40.
79. Seo D, Ginsburg GS, Goldschmidt-Clermont PJ. Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. J Am Coll Cardiol 2006; 48: 227-35.
80. Tuomisto TT, Korkeela A, Rutanen J, Viita H, Brasen JH, Riekkinen MS, et al. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler Thromb Vasc Biol 2003; 23: 2235-40.
81. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004; 109: 1966-72.
82. Mayr M, Madhu B, Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc Med 2007; 17: 43-8.
83. Miller DT, Ridker PM, Libby P, Kwiatkowski DJ. Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 2007; 49: 1589-99.
84. Davidsson P, Hulthe J, Fagerberg B, Olsson BM, Hallberg C, Dahllof B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005; 46: 1999-2006.
85. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 1431-45.
86. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 551-65.
87. Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Mouls L, et al. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 2008; 7: 290-8.
88. Berhane BT, Zong C, Liem DA, Huang A, Le S, Edmondson RD, et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005; 5: 3520-30.
89. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005; 112: 3868-75.
90. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008; 453: 393-400.